Trial Profile
A Pilot Study to Evaluate the Efficacy and Safety of GFT505 (80mg) Orally Administered Once Daily for 12 Weeks in Patients With Type 2 Diabetes Mellitus. A Multicentre, Randomised, Double Blind, Placebo-Controlled Study.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Elafibranor (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- 27 May 2013 A combined analysis of four phase IIa studies was published in Hepatology, according to a GENFIT media release.
- 12 Jul 2011 Status changed from recruiting to completed according to the ClinicalTrials.gov record.
- 12 Jul 2011 Results have been reported in a Genfit media release. These findings will also be presented at EASD-2011.